However, the side effects and continued high cost of these medications present significant access barriers, limiting their potential public health impact
No specific products are officially endorsed for use with these treatments, and individual needs vary considerably
However, not everyone will see the same results
Both TNF- and IL-6 can reduce the expression of intracellular glucose transporter 4 (GLUT4), inhibit normal phosphorylation of insulin receptors and insulin receptor substrate 1 (IRS-1), block GLUT4 translocation, and lead to IR
These adaptations persist even after weight loss stabilizes, creating a biological drive to return to the previous weight set point
Conclusion Gastroparesis represents a serious potential complication for patients using Ozempic and other GLP-1 receptor agonist medications